• Halozyme priced an upsized private offering of USD 1.3 billion 1.5% convertible senior notes due 2033.
• Deal increased from the previously announced USD 1.05 billion size.
• Initial purchasers received a 13-day option to buy up to an additional USD 200 million of the notes.
• Net proceeds expected at about USD 1.28 billion, rising to about USD 1.47 billion if the option is fully exercised.
• Part of proceeds earmarked to repurchase USD 151.7 million of 2027 notes, USD 220 million of 2028 notes, with remaining funds for general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609172320PR_NEWS_USPR_____LA51286) on September 18, 2026, and is solely responsible for the information contained therein.